Awad MM, et al. - Researchers assessed if treatment with MET inhibitors effects median overall survival (mOS) in patients with METex14 non-small cell lung cancer (NSCLC) in this multicenter retrospective analysis. The median age was 72 years among 148 patients with METex14 NSCLC. Overall survival is improved in patients with METex14 NSCLC after treatment with a MET inhibitor. The mOS was 24.6 months in the 27 metastatic patients who received at least one MET inhibitor vs a mOS of 8.1 months in the 34 metastatic patients who never received a MET inhibitor.